FDA investigation of RU-486 death reports
Executive Summary
FDA is "obtaining more information" about a recent death associated with Danco's abortifacient Mifeprex (mifepristone). Since the drug's approval in September 2000, FDA has received three other reports (one each in the U.S., Canada and U.K.) of women who died and were taking mifepristone, but says it is "unlikely that these deaths were caused by" the drug. FDA will "continue to monitor adverse events with this particular drug, as it does with all drugs," the agency says...
You may also be interested in...
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.